ASPI · ASP Isotopes Inc. · Insider Trading

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.93 to $3.075, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

The securities to which this filing relates are held directly by certain funds and accounts ("AK Jensen Funds") to which AK Jensen Investment Management Limited ("AK Jensen") serves as the investment manager. Anders K. Jensen ("Mr. Jensen") and Duncan P. Saville ("Mr. Saville") may be deemed to indirectly control AK Jensen. AK Jensen and Messrs. Jensen and Saville disclaim beneficial ownership of the Issuer's securities reported herein except to the extent of their pecuniary interest therein, if any.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

The securities to which this filing relates are held directly by certain funds and accounts ("AK Jensen Funds") to which AK Jensen Investment Management Limited ("AK Jensen") serves as the investment manager. Anders K. Jensen ("Mr. Jensen") and Duncan P. Saville ("Mr. Saville") may be deemed to indirectly control AK Jensen. AK Jensen and Messrs. Jensen and Saville disclaim beneficial ownership of the Issuer's securities reported herein except to the extent of their pecuniary interest therein, if any.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.39 to $2.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

The securities to which this filing relates are held directly by certain funds and accounts ("AK Jensen Funds") to which AK Jensen Investment Management Limited ("AK Jensen") serves as the investment manager. Anders K. Jensen ("Mr. Jensen") and Duncan P. Saville ("Mr. Saville") may be deemed to indirectly control AK Jensen. AK Jensen and Messrs. Jensen and Saville disclaim beneficial ownership of the Issuer's securities reported herein except to the extent of their pecuniary interest therein, if any.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.23 to $3.475, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

The securities to which this filing relates are held directly by certain funds and accounts ("AK Jensen Funds") to which AK Jensen Investment Management Limited ("AK Jensen") serves as the investment manager. Anders K. Jensen ("Mr. Jensen") and Duncan P. Saville ("Mr. Saville") may be deemed to indirectly control AK Jensen. AK Jensen and Messrs. Jensen and Saville disclaim beneficial ownership of the Issuer's securities reported herein except to the extent of their pecuniary interest therein, if any.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.015 to $3.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

The securities to which this filing relates are held directly by certain funds and accounts ("AK Jensen Funds") to which AK Jensen Investment Management Limited ("AK Jensen") serves as the investment manager. Anders K. Jensen ("Mr. Jensen") and Duncan P. Saville ("Mr. Saville") may be deemed to indirectly control AK Jensen. AK Jensen and Messrs. Jensen and Saville disclaim beneficial ownership of the Issuer's securities reported herein except to the extent of their pecuniary interest therein, if any.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.98 to $3.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

The securities to which this filing relates are held directly by certain funds and accounts ("AK Jensen Funds") to which AK Jensen Investment Management Limited ("AK Jensen") serves as the investment manager. Anders K. Jensen ("Mr. Jensen") and Duncan P. Saville ("Mr. Saville") may be deemed to indirectly control AK Jensen. AK Jensen and Messrs. Jensen and Saville disclaim beneficial ownership of the Issuer's securities reported herein except to the extent of their pecuniary interest therein, if any.

Open market purchase transactions.

Open market purchase transactions.

Open market purchase transactions.

Open market purchase transactions.

This award of common stock with a market value of $100,000 on January 14, 2024 was made in connection with the appointment of Mr. Ryan to the board of directors effective January 14, 2024, as previously disclosed in the issuer's Form 8-K filed on January 18, 2024.

This award of common stock with a market value of $100,000 on October 23, 2023 was made in connection with the appointment of Mr. Gorley to the board of directors effective October 23, 2023, as previously disclosed in the issuer's Form 8-K filed on October 23, 2023.

On December 30, 2022, the Company issued 1,000,000 shares of the Company's restricted common stock to Paul Mann as a bonus for services provided during the fiscal year ended December 31, 2022.

On December 30, 2022, the Company issued 50,000 shares of the Company's restricted common stock to Robert Ainscow as a bonus for services provided during the fiscal year ended December 31, 2022.

This special one-time equity award of 200,000 restricted shares was contingent upon the completion of our IPO. Mr. Moore will receive 100,000 restricted shares of our common stock on November 15, 2023 and 100,000 restricted shares of our common stock on November 15, 2024.

This special one-time equity award of 200,000 restricted shares was contingent upon the completion of our IPO. Mr. Wider will receive 100,000 restricted shares of our common stock on November 15, 2023 and 100,000 restricted shares of our common stock on November 15, 2024.

This special one-time equity award of 600,000 restricted shares were contingent upon the completion of our IPO. Mr. Vasnetsov will receive 150,000 restricted shares of our common stock on November 15, 2023, 150,000 restricted shares of our common stock on November 15, 2024, 150,000 restricted shares of our common stock on November 15, 2025, and 150,000 shares of our restricted common stock on November 15, 2026.

Mr. Vasnetsov beneficially owns 1,000,000 shares indirectly through Elista LLC and beneficially owns 1,800,000 shares indirectly through ChemBridges LLC.

This special one-time equity award of 1,000,000 restricted shares was contingent upon the completion of our IPO. Mr. Mann will receive 250,000 restricted shares of our common stock on November 15, 2023, 250,000 restricted shares of our common stock on November 15, 2024, 250,000 restricted shares of our common stock on November 15, 2025, and 250,000 shares of our restricted common stock on November 15, 2026.

This special one-time equity award of 600,000 restricted shares was contingent upon the completion of our IPO. Mr. Ainscow will receive 150,000 restricted shares of our common stock on November 15, 2023, 150,000 restricted shares of our common stock on November 15, 2024, 150,000 restricted shares of our common stock on November 15, 2025, and 150,000 shares of our restricted common stock on November 15, 2026.

This special one-time equity award of 200,000 restricted shares was contingent upon the completion of our IPO. Mr. Donfeld will receive 100,000 restricted shares of our common stock on November 15, 2023 and 100,000 restricted shares of our common stock on November 15, 2024.

The special one-time award of 200,000 restricted shares were contingent upon the completion of our IPO. Dr. Strydom will receive 100,000 restricted shares of our common stock on November 15, 2023 and 100,000 restricted shares of our common stock on November 15, 2024.

Dr. Strydom beneficially owns 3,797,423 shares indirectly through Tianne Holdings (Pty) Ltd.